Lupin, Aurobindo Pharma unit recall products from US over manufacturing issues
New Delhi: According to the US health regulator, Lupin and a unit of Aurobindo Pharma are recalling products from the American market over manufacturing issues.
Specifically, a US-based Lupin unit Lupin Pharmaceuticals Inc is recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) used to treat bacterial infections.
The Company is recalling the medication due to "failed content uniformity specifications".
The affected lot has been produced at the company's Mandideep-based manufacturing plant in Madhya Pradesh.
The company commenced the Class II nationwide (US) recall on May 30 this year.
According to PTI, the US health regulator stated that New Jersey-based Eugia US LLC, a subsidiary of Aurobindo Pharma, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection USP.
The company is recalling the affected lot due to "failed impurities/degradation specifications", USFDA said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.